Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Primary Purpose
Oral Mucositis
Status
Unknown status
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
LLLT :low level laser therapy
Sponsored by
About this trial
This is an interventional prevention trial for Oral Mucositis focused on measuring Children, Cancer, Mucositis, Laser, Prevention, Chemotherapy, Children with malignancies receiving chemotherapy and/or radiotherapy inducing severe mucositis
Eligibility Criteria
Inclusion Criteria:
- 0 at 18 years
- patients receiving therapy with agents likely to cause severe mucositis (grade 3 or 4)
- Patients who had developed severe mucositis previously in any chemotherapy, and receiving the same.
- Healthy oral mucosa
- informed consent
Exclusion Criteria:
- - Infection active and proved, viral, bacterial or fungal oral cavity
- Malignant pathology in the oral cavity
- Preliminary local irradiation of the oral cavity
- Simultaneous treatment by an agent of prevention or treatment of mucositis in investigation
- Inclusion in a protocol with oral mucositis as one of the assessment criteria
- Absence of consent lit by parents or child
Sites / Locations
- CHU Clermont-FerrandRecruiting
Outcomes
Primary Outcome Measures
Mucositis scale - World Health Organization (WHO)
Secondary Outcome Measures
Mucositis period
Mucositis free survival
Pain intensity
Morphinic administration
Duration of hospitalisation
Febrile neutropenia
Duration of parenteral nutrition
Psychological impact
Full Information
NCT ID
NCT01007617
First Posted
November 3, 2009
Last Updated
January 18, 2011
Sponsor
University Hospital, Clermont-Ferrand
Collaborators
Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, CHU de Clermont-Ferrand, Faculté de chirurgie dentaire, Clermont-Ferrand, Centre de Pharmacologie Clinique, INSERM CIC 501, Laboratoire des Matériaux Inorganiques, ESA CNRS 6002 et ENSCCF, Université Blaise-Pascal, Aubière
1. Study Identification
Unique Protocol Identification Number
NCT01007617
Brief Title
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Official Title
Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1"
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Unknown status
Study Start Date
June 2009 (undefined)
Primary Completion Date
July 2010 (Anticipated)
Study Completion Date
July 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University Hospital, Clermont-Ferrand
Collaborators
Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, CHU de Clermont-Ferrand, Faculté de chirurgie dentaire, Clermont-Ferrand, Centre de Pharmacologie Clinique, INSERM CIC 501, Laboratoire des Matériaux Inorganiques, ESA CNRS 6002 et ENSCCF, Université Blaise-Pascal, Aubière
4. Oversight
5. Study Description
Brief Summary
Oral mucositis represents a major complication of cytotoxic chemotherapy among cancer in children. Low-power laser therapy (LPLT) has been used to reduce the incidence of oral mucositis in patients who are receiving high-dose chemotherapy. The aim of this study is to compare two preventives energies delivered of LPLT to oral mucosa in decreasing the severity of mucositis in children.
Detailed Description
Mucositis is one of the main complications of cytotoxic chemotherapy and total body irradiation in children cancers. Local and systemic treatments are not efficiency or limited by side effects, (particularly for opioid). Two randomized recent studies in adult have showed the efficiency of LPLT (wavelength 650nm at the intensity of 4J/cm²) in prevention of severe mucositis. In pediatrics patient, only one randomized study was performed to the same intensity of 4J/cm² but with a wavelength of 732nm, and did not show the evidence of profit. In theory, tissues absorption level of laser is similar at 650 and 900nm but lower around 700nm. Procedure was very well tolerated by children; the main limiting factor is the deadline directly proportional to intensity delivered.
The aim of our study is to compare two preventives energies (2J/cm² or 8 J/cm²) daily delivered of LPLT to oral mucosa in decreasing the severity of mucositis in children. Placebo study was not possible to our opinion and we preferred to compare two intensity of LPLT for three reasons : being given the sensation of heat generated by the treatment, a true placebo is difficult to obtain; considering the difficulties proceeding to large-sized clinical trials in this population, it seems to us necessary to end quickly in an optimal protocol; the main inconvenience of LPLT is the duration of the sessions, so in case of negative result, our study will generate data allowing not to realize useless too long sessions.
It's a prospective controlled study, randomized in double blind phase II, in one center. All the patients will receive LPLT (GaAlAs, wavelength 980nm) daily of the 1st in the 5th day of cytotoxic treatment. The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.
Main evaluation criteria: mucositis maximal intensity (WHO scale) Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition.
Expected clinical effects: improvement of the children's comfort; dissemination of the technique in the other oncology pediatric centers
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Mucositis
Keywords
Children, Cancer, Mucositis, Laser, Prevention, Chemotherapy, Children with malignancies receiving chemotherapy and/or radiotherapy inducing severe mucositis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
LLLT :low level laser therapy
Intervention Description
The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.
Main evaluation criteria: mucositis maximal intensity (WHO scale).
Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition.
Primary Outcome Measure Information:
Title
Mucositis scale - World Health Organization (WHO)
Time Frame
after delivering a dose of 2 J/cm2/d
Secondary Outcome Measure Information:
Title
Mucositis period
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Mucositis free survival
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Pain intensity
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Morphinic administration
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Duration of hospitalisation
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Febrile neutropenia
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Duration of parenteral nutrition
Time Frame
after delivering a dose of 8 J/cm2/d
Title
Psychological impact
Time Frame
after delivering a dose of 8 J/cm2/d
10. Eligibility
Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
0 at 18 years
patients receiving therapy with agents likely to cause severe mucositis (grade 3 or 4)
Patients who had developed severe mucositis previously in any chemotherapy, and receiving the same.
Healthy oral mucosa
informed consent
Exclusion Criteria:
- Infection active and proved, viral, bacterial or fungal oral cavity
Malignant pathology in the oral cavity
Preliminary local irradiation of the oral cavity
Simultaneous treatment by an agent of prevention or treatment of mucositis in investigation
Inclusion in a protocol with oral mucositis as one of the assessment criteria
Absence of consent lit by parents or child
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick LACARIN
Phone
04.73.75.11.95
Email
placarin@chu-clermontferrand.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Etienne MERLIN, MD
Organizational Affiliation
University Hospital, Clermont-Ferrand
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick LACARIN
Phone
04.73.75.11.95
Email
placarin@chu-clermontferrand.fr
12. IPD Sharing Statement
Learn more about this trial
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
We'll reach out to this number within 24 hrs